RICHMOND, British Columbia, Dec. 8, 2005 (PRIMEZONE) -- BioCurex Inc. (Pink Sheets:BOCX) announced today that Dr. Steward Sell has joined the Scientific Advisory Board of BioCurex Inc.
Dr. Sell is an internationally renowned physician and scientist in the cancer and stem cell fields. He obtained his medical degree at the University of Pittsburgh, his residency in Pathology at Massachusetts General Hospital and research in Immunology at National Institute of Health, Bethesda and University of Birmingham. He has received many awards including the Virchow Award (in honor of the recognized father of pathology), Legacy Laureate of the University of Pittsburgh, (which recognizes the University's most distinguished graduates), Distinguished Scientist by the International Academy of Tumor Marker Oncology, the Gary Miller Memorial Award from the American Association for Cancer Research (AACR) and recently, a special award from the AACR for his contributions to teaching principles of cancer biology over the last 25 years.
Dr. Sell has published over 360 papers and chapters and has edited or written 14 Books. One of his books, "Basic Immunology" received honorable mention in 1988 from the American Medical Writers Association. With Dr. P. G. H. Gell, he was the first to demonstrate antibody-like receptors on lymphocytes. This was described in a paper that has been listed as a "Citation Classic" (as in most quoted papers) by Current Contents Magazine.
Dr. Sell has held many academic positions at various institutions and is presently Research Physician at the Wadsworth Center, New York State Dept. of Health as well as Professor at the State University of New York. He has served on many academic and national advisory boards, and is .the Editor-in-Chief of a new journal: Stem Cell Reviews, published by Humana Press.
To know more visit http://www.leadershipmedica.com/sommari/2005/numero_07/medicina/sessione_1/articolo_ing/interfaccia.htm
Dr. Gold, Chairman of the Scientific Advisory Board commented: "We are extremely pleased to have a scientist as distinguished and recognized as Dr. Sell. His contributions to the field of cancer research have been very significant and we welcome his input to our Company as we move forward in developing the RECAF technology to its full potential."
Dr. Sell noted: "The preliminary data showing expression of RECAF on histologic sections and detection in serum of cancer patients indicates great promise, not only for use by pathologists for diagnosis of cancer in difficult cases, but also as an serum marker for the early detection of cancer. The serum marker could be critically applied to patients who are at a high risk or have equivocal findings, such as questionably positive density on a mammogram or marginally elevated PSA".
He then added: "I am excited about the work you are doing and am delighted to be able to take an active part in the development of your projects."
Dr. Moro, President, CEO stated, "We re very fortunate to be able to attract the interest of a figure like Dr. Sell. He is not only an excellent pathologist, scientist and educator; he is also one of the prominent figures in tumor biology and cancer immunotherapy. We are thrilled by him joining our Scientific Advisory Board; an addition that we anticipate will be extremely fruitful for our company."
BioCurex's Scientific Advisory Board includes the creators of the cancer marker field: Dr. Phil Gold, C.C., O.Q., M.D., Ph.D., who discovered CEA and Dr. Garri Abelev Ph.D., M.D. (Russia), who discovered the first cancer marker, AFP, and Dr. Jose Uriel, Ph.D., M.D., former Director of the National Cancer Institute (France).
Dr. M.J. Villacampa, Ph.D. is also a pioneer of RECAF (Spain), Dr. Strath Wilson, Ph.D. (Canada), Dr. T. Tamaoki, Ph.D. who cloned the first cancer marker (Japan), Dr. E. Alpert, M.D., Ph.D., a member of the New York Academy of Sciences (USA), Dr. Michel Sadelain, M.D., Ph.D., Director of one of the handful of gene therapy units approved by the FDA in the USA (Sloan-Kettering Memorial, National Cancer Institute, USA) are also members of BioCurex's Scientific Advisory Board.
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAFtm, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.
BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAFTM Cancer technology as outlined in a joint press release dated March 29, 2005. The release noted that the cancer marker RECAFTM has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others.
To read more about the Company, please visit the News section in our web site (www.biocurex.com).
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.